ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
17β-Estradiol Maintains Mitochondrial Homeostasis in Osteoblasts by Inhibiting MMP-8 and Activating the Ras Signaling Pathway in Postmenopausal Osteoporosis.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
17β-estradiol is a potent endogenous estrogen used for postmenopausal osteoporosis treatment. Its osteoprotective role correlates with matrix metalloproteinase (MMP) and mitochondrial homeostasis. This research sought to examine the role of 17β-estradiol on MMP-8 in mitochondrial homeostasis and elucidate the potential regulatory pathways. We evaluated the effects of 17β-estradiol on MMP-8, bone loss, osteogenic differentiation, and mitochondrial homeostasis in bilateral ovariectomy (OVX)-induced mice and MC3T3-E1 cells. MMP-8 was overexpressed to validate its regulatory relationship with 17β-estradiol. Comprehensive analyses were further conducted to identify the potential pathways associated with MMP-8. The Ras pathway agonist ML-099 and inhibitor Lonafarnib were used for pathway validation. 17β-estradiol treatment attenuated bone loss and increased osteogenic Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.